IP Library › Granted Patent US 7,879,793
Granted Patent B2
US 7,879,793 · App. 11/874,316 · Granted Feb 1, 2011

Treatment of medical condition with A2 domain of von willebrand factor

Assignee: Baylor College of Medicine
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,879,793
App. No.
11/874,316
Granted
Feb 1, 2011
Kind
B2
Abstract

The present invention is directed to methods for the prevention, treatment and/or diagnosis of a medical condition, such as sepsis, systemic inflammatory reaction syndrome, and/or thrombosis, for example. In particular, the method employs part or all of the A2 domain of von Willebrand factor. In certain cases, a recombinant A2 domain is utilized for the treatment of sepsis, systemic inflammatory reaction syndrome, and/or thrombosis, for example.

Claims (9)

1. A method of treating one or more of sepsis, thrombosis, and systemic inflammatory reaction syndrome (SIRS) in an individual, comprising delivering to the individual a therapeutically effective amount of an A2 domain of von Willebrand factor, or a functionally active fragment of said A2 domain, wherein said A2 domain of von Willebrand factor or said functionally active fragment of said A2 domain is further defined as a polypeptide comprising at least 75% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, at least 97% identity, at least 98% identity, or at least 99% identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, or SEQ ID NO:30 that inhibits ristocetin-induced platelet agglutination, shear-induced platelet aggregation, and platelet adhesion to collagen under flow conditions.

2. The method of claim 1 , wherein the A2 domain is delivered to the individual as a polypeptide.

3. The method of claim 2 , wherein the polypeptide is comprised in a carrier.

4. The method of claim 3 , wherein the carrier comprises lipid.

5. The method of claim 3 , wherein the carrier comprises liposome.

6. The method of claim 1 , wherein the individual is a patient in a hospital.

7. The method of claim 1 , wherein the individual has undergone surgery, is undergoing surgery, or will undergo surgery.

8. The method of claim 1 , wherein the A2 domain is delivered intravenously.

9. The method of claim 1 , further comprising delivering one or more antibiotics to the individual.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2008
From: CRUZ, MIGUEL A.
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 022004/0354 →
Continuity (3)
Provisional Application 60852482 · Oct 18, 2006
Provisional Application 60890910 · Feb 21, 2007
Related Publication 20090118161A1 · May 7, 2009